OBIO
HealthcareOrchestra BioMed Holdings, Inc.
$4.24
$-0.07 (-1.62%)
Jan 5, 2026
Price History (1Y)
Analysis
Orchestra BioMed Holdings, Inc. is a biotechnology company in the healthcare sector with approximately 70 employees. The company has a market capitalization of $239.41 million and generates revenue of $2.82 million on a trailing twelve-month basis. Financially, Orchestra BioMed Holdings reports significant losses, with a net income of -$75,101,000 and EBITDA of -$74,909,000 over the same period. The company's gross margin is 93.0%, while its operating and profit margins are -2359.2% and 0.0%, respectively. In terms of returns, Orchestra BioMed Holdings has a return on equity (ROE) of -167.0% and a return on assets (ROA) of -52.2%. The company's debt-to-equity ratio is 36.66, and it maintains a current ratio of 4.73. Orchestra BioMed Holdings' valuation metrics include a forward P/E ratio of -2.71, an EV/EBITDA ratio of -2.18, and a price to book ratio of 5.47. The company's revenue growth rate is -12.8% year-over-year, while earnings growth is not reported.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $239.41M
- P/E Ratio
- N/A
- 52-Week High
- $6.16
- 52-Week Low
- $2.20
- Avg Volume
- 304.56K
- Beta
- 0.63
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 70